DBCO-PEG₄-马来酰亚胺 | 1480516-75-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: DBCO-PEG₄-马来酰亚胺
• 中文别名: 二苯并环辛炔-PEG4-胺-马来酰亚胺
• 英文名称: DBCO-PEG4-Maleimide
• 英文别名: N-[2-[2-[2-[2-[3-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethyl]-3-(2,5-dioxopyrrol-1-yl)propanamide
• CAS: 1480516-75-3
• 化学式: C₃₆H₄₂N₄O₉
• 分子量: 674.7
• InChiKey: VVFZXPZWVJMYPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  49
• 可旋转键数：
  21
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  9

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] METHODS AND COMPOSITIONS FOR TREATING ALLERGY AND INFLAMMATORY DISEASES<br/>[FR] MÉTHODES ET COMPOSITIONS DE TRAITEMENT D'ALLERGIE ET LES MALADIES INFLAMMATOIRES
  申请人：BAYLOR RES INST

  公开号：WO2015187637A1

  公开（公告）日：2015-12-10

  Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.

  本文描述了使用Th2通路的免疫调节剂治疗过敏和炎症性疾病的治疗方法。其中，揭示的方面涉及降低需要减少Th2型细胞反应的受试者的方法，包括向受试者施用与TLR激动剂操作性连接的抗Dectin-1抗体或抗原结合片段的治疗有效剂量。
• MODIFIED HELICASES
  申请人：Oxford Nanopore Technologies Limited

  公开号：EP3741847A1

  公开（公告）日：2020-11-25

  The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

  本发明涉及改良的螺旋酶，它能减少与多核苷酸的解结合。这种螺旋酶可用于控制多核苷酸的移动，尤其适用于多核苷酸的测序。
• Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
  申请人：PFIZER INC.

  公开号：US10653794B2

  公开（公告）日：2020-05-19

  An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.

  一种在哺乳动物细胞中生产抗体的工艺，在这种工艺中，经过设计的未配对半胱氨酸残基被翻译后修饰，并用特定的化学实体封端，这种封端抗体非常适合进一步的特定位点共轭步骤，以形成抗体-药物共轭物（ADC）或蛋白药物共轭物；使用这些封端抗体生产的 ADC，尤其包括通过选择性还原封端抗体的半胱氨酸残基而形成的 ADC，以及使用醛/吖啶/炔双交基等化学处理形成的 ADC，这些化学处理允许进行额外的药物共轭化学反应；以及由细胞在低半胱氨酸、半胱氨酸和谷胱甘肽介质中产生的未封端抗体，以及通过直接与这些未封端抗体共轭而生产的 ADC。
• Modified helicases
  申请人：Oxford Nanopore Technologies Ltd.

  公开号：US10724018B2

  公开（公告）日：2020-07-28

  The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

  本发明涉及一种表征目标多核苷酸的新方法。该方法使用一个孔和一个 Dda 螺旋酶。螺旋酶控制目标多核苷酸通过孔道。本发明还涉及经修饰的 Dda 螺旋酶，它可用于控制多核苷酸的运动，尤其适用于多核苷酸的测序。
• Modified enzymes
  申请人：Oxford Nanopore Technologies Ltd.

  公开号：US11180741B2

  公开（公告）日：2021-11-23

  The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

  本发明涉及经修饰的 Dda 螺旋酶，可用于控制多核苷酸的移动，尤其适用于多核苷酸的测序。